





Stryka-001 Treatments for Enhanced Muscle Regeneration in FSHD Patients

**Presenter
Ryan Wuebbles, PhD.**


STRYKA-001

- Enhancer of muscle regeneration through elevated $\alpha 7\beta 1$ Integrin expression
- The enhanced regeneration increases muscle strength and prevents fibrosis after insult
- Stryka-001 is already FDA-approved for another indication and can potentially be fast-tracked




Preclinical FSHD mouse studies using Stryka-001 began February 2018

Acute Dux4 FSHD Model




Chronic Dux4 FSHD Model



This project was funded by FSH Society


Acute DUX4 Expression Data



These were the second group to be started and thus the new FSHD mouse cohort just began treatments.

Chronic DUX4 Expression

These studies will conclude in November.



Early Conclusions

- Preliminary data suggests that Stryka-001 therapeutic is a viable stand alone treatment for FSHD patient use.
- Clinical trial planning will begin within 12-months, with an optimistic start in 1.5 years.
- Stryka-001 could potentially be used in combination with other FSHD therapeutics including myostatin inhibitors, immune modulators, and Dux4 inhibiting small molecules or DUX4 gene therapy methodologies with enhanced efficacy.



Ryan Wuebbles, PhD
UNR Research Assistant Professor

Dean Burkin, PhD
UNR Professor

Peter Jones, PhD
UNR Associate Professor

Andrea Nunes, PhD
Postdoctoral Fellow

Takako Jones, PhD
UNR Research Associate Professor

Tatiana Fontelonga, MS
UNR Graduate Student

Pamela Barraza
UNR Graduate Student

Christina Smith
UNR Graduate Student

Dean Burkin, PhD
CEO Strykagen Corp.

Ryan Wuebbles, PhD
CSO Strykagen Corp.

David Maine
CFO StrykaGen Corp.

Mark Stone
CEO FSH Society

June Kinoshita
CSPO, FSH Society

Dan Perez
CSO, FSH Society

Contact: ryan@strykagen.com